Medifast, Inc.
NYSE:MEDPersonal Products & Services
-$0.01 today
- Market cap
- $136.43M
- Beta
- 0.66
- P/E (TTM)
- -6.2
- EPS (TTM)
- -$1.82
Volume 0.09M
Average 0.21M
MED Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Medifast, Inc.NYSE: MED
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization grows, but more slowly than its trailing trend
Q1 FY2026 depreciation & amortization of $3.48M rose 6.2% year over year, behind the +13.5% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 0.5% from the prior quarter. Over 3 fiscal years it compounded at -1.5% a year.
Context
- Depreciation & amortization amounted to 2.7% of revenue in FY2025, up 0.6 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +6.2% toward the trailing-twelve-month pace of +13.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 10.5M USD
- Year-over-year change
- -17.4%
- 4-year CAGR
- +11.4%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 10.5M | -17.4% |
| FY2024 | 2024-12-31 | 12.71M | -3.1% |
| FY2023 | 2023-12-31 | 13.11M | +19.4% |
| FY2022 | 2022-12-31 | 10.98M | +61.2% |
| FY2021 | 2021-12-31 | 6.81M | — |
Depreciation & Amortization vs competitors
How MED compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +13.5% is the 2nd highest of 10, against a peer median of -15.3%.
- Depreciation & amortization amounts to 4.2% of revenue for MED, versus a peer median of 4.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| FY2025 | HK$66.6M HKD | -15.3% | -1.0% | 14.5% | |
| LTM May 2026 | $64.45M USD | -16.0% | -4.4% | 6.6% | |
| LTM Mar 2026 | $18.11M USD | +2.5% | -4.4% | 3.0% | |
| LTM Mar 2026 | $14.45M USD | +13.5% | -1.5% | 4.2% | |
| LTM Mar 2026 | $12.2M USD | -9.3% | -18.6% | 4.8% | |
| LTM Feb 2026 | $8.79M USD | -7.5% | -4.3% | 2.6% | |
| LTM Dec 2025 | $8.27M USD | -59.1% | -17.3% | 1.1% | |
| LTM Jan 2026 | $6.3M USD | +57.4% | +19.8% | 2.2% | |
| LTM Mar 2026 | $4.36M USD | -20.4% | +0.3% | 4.9% | |
AIIORobo.ai Inc. | FY2025 | $1.6M USD | -54.8% | +28.9% | 168.6% |
| Peer median (excluding MED) | — | -15.3% | -4.3% | 4.8% | |
Competitors are the stored peer set for MED. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.53B | 1.6B | 1.07B | 602.46M | 385.79M |
| Cost of Revenue | 398.49M | 458.16M | 296.2M | 157.84M | 110.6M |
| Gross Profit | 1.13B | 1.14B | 775.85M | 444.62M | 275.19M |
| Gross Margin | 73.9% | 71.3% | 72.4% | 73.8% | 71.3% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 911.36M | 955.61M | 649.45M | 441.75M | 289.4M |
| Operating Expenses | 911.36M | 955.61M | 649.45M | 441.75M | 289.4M |
| Depreciation & Amortization | 6.81M | 10.98M | 13.11M | 12.71M | 10.5M |
| EBITDA | 222.94M | 195.74M | 141.9M | 16.49M | 4.86M |
| EBITDA Margin | 14.6% | 12.2% | 13.2% | 2.7% | 1.3% |
| Operating Income | 216.24M | 184.81M | 126.4M | 2.88M | (14.21M) |
| Operating Margin | 14.2% | 11.6% | 11.8% | 0.5% | -3.7% |
| Interest Income | 0 | 0 | 2.49M | 4.8M | 5.52M |
| Interest Expense | 231K | 701K | 0 | 0 | 0 |
| Other Income / Expenses | (112K) | (747K) | 2.4M | 909K | 8.57M |
| Income Before Tax | 216.13M | 184.06M | 128.8M | 3.79M | (5.64M) |
| Pre-Tax Margin | 14.2% | 11.5% | 12.0% | 0.6% | -1.5% |
| Income Tax Expense | 52.1M | 40.49M | 29.38M | 1.7M | 13.03M |
| Net Income | 164.03M | 143.57M | 99.42M | 2.09M | (18.67M) |
| Net Margin | 10.7% | 9.0% | 9.3% | 0.3% | -4.8% |
| EPS (Basic) | 14.01 | 12.82 | 9.10 | 0.19 | (1.70) |
| EPS (Diluted) | 13.89 | 12.73 | 9.10 | 0.19 | (1.70) |
| Weighted Avg Shares | 11.71M | 11.2M | 10.88M | 10.93M | 10.98M |
| Weighted Avg Shares (Diluted) | 11.81M | 11.28M | 10.92M | 10.96M | 10.98M |
Medifast, Inc.
NYSE:MED
Intrinsic Alpha fair value
Locked
Current Price
$12.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.